192 related articles for article (PubMed ID: 17875803)
1. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
2. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
Evens AM; Spies WG; Helenowski IB; Patton D; Spies S; Jovanovic BD; Miyata S; Hamilton E; Variakojis D; Chen J; Naumovski L; Rosen ST; Winter JN; Miller RA; Gordon LI
Clin Cancer Res; 2009 Oct; 15(20):6462-71. PubMed ID: 19825958
[TBL] [Abstract][Full Text] [Related]
3. The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
Laoruangroj C; Atherton PJ; Wiseman GA; Ansell S; Feldman AL; Schumacher P; Witzig TE
Leuk Lymphoma; 2024 Mar; 65(3):333-338. PubMed ID: 38189774
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Durando M; Gopal AK; Tuscano J; Persky D
Oncologist; 2024 Apr; 29(4):278-288. PubMed ID: 38207010
[TBL] [Abstract][Full Text] [Related]
5. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr.
Mondello P; Cuzzocrea S; Navarra M; Mian M
Oncotarget; 2016 Feb; 7(7):7597-609. PubMed ID: 26657116
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.
Dillman RO
Clin Exp Med; 2006 Mar; 6(1):1-12. PubMed ID: 16550338
[TBL] [Abstract][Full Text] [Related]
7. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
8. Pre-dosing with lilotomab prior to therapy with
Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
[TBL] [Abstract][Full Text] [Related]
9. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
Au KM; Tripathy A; Lin CP; Wagner K; Hong S; Wang AZ; Park SI
ACS Nano; 2018 Feb; 12(2):1544-1563. PubMed ID: 29361211
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.
Zhang MM; Gopal AK
Semin Hematol; 2008 Apr; 45(2):118-25. PubMed ID: 18381107
[TBL] [Abstract][Full Text] [Related]
11. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.
Jacobs SA
Biologics; 2007 Sep; 1(3):215-27. PubMed ID: 19707332
[TBL] [Abstract][Full Text] [Related]
12. Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.
Lehnert M; Ludwig H; Zojer N
Onco Targets Ther; 2009 Feb; 2():199-208. PubMed ID: 20616907
[TBL] [Abstract][Full Text] [Related]
13. Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.
Calais PJ; Turner JH
World J Nucl Med; 2012 Sep; 11(3):110-6. PubMed ID: 23372448
[TBL] [Abstract][Full Text] [Related]
14.
Wang J; Baidoun F; Tun HW; Alhaj Moustafa M
Blood Lymphat Cancer; 2023; 13():59-65. PubMed ID: 37810176
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.
Othman T; Lowsky R; Richman C; Hoeg R; Abedi M; Tuscano J
Bone Marrow Transplant; 2023 Oct; 58(10):1143-1145. PubMed ID: 37391654
[No Abstract] [Full Text] [Related]
16. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
Marchesi F; Pimpinelli F; Giannarelli D; Ronchetti L; Papa E; Falcucci P; Pontone M; Di Domenico EG; di Martino S; Laquintana V; Mandoj C; Conti L; Cordone I; La Malfa A; Viggiani C; Renzi D; Palombi F; Romano A; Pisani F; Gumenyuk S; Di Bella O; Vujovic B; Morrone A; Ciliberto G; Ensoli F; Mengarelli A
Leukemia; 2022 Feb; 36(2):588-590. PubMed ID: 34545184
[No Abstract] [Full Text] [Related]
17. Advances and application of radioimmunotherapy in non-Hodgkin lymphoma.
Stevens PL; Oluwole O; Reddy N
Am J Blood Res; 2012; 2(2):86-97. PubMed ID: 22762027
[TBL] [Abstract][Full Text] [Related]
18. Development of DOTA-Rituximab to be Labeled with
Johari Doha F; Rahmani S; Rikhtechi P; Rasaneh S; Sheikholislam Z; Shahhosseini S
Iran J Pharm Res; 2017; 16(2):619-629. PubMed ID: 28979315
[TBL] [Abstract][Full Text] [Related]
19. CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
Li Y
N Engl J Med; 2019 Jan; 380(5):497. PubMed ID: 30702241
[No Abstract] [Full Text] [Related]
20. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Volkmer JP; Chao MP
N Engl J Med; 2019 Jan; 380(5):497-498. PubMed ID: 30699313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
